These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 31879191

  • 1. Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion-Positive Metastatic Lung Cancer.
    Hochmair MJ, Setinek U, Krenbek D, Fazekas A, Illini O, Weinlinger C, Draxler H, Marcher M, Valipour A, Müllauer L, Beer L.
    Clin Lung Cancer; 2020 Mar; 21(2):e49-e53. PubMed ID: 31879191
    [No Abstract] [Full Text] [Related]

  • 2. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
    DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, Pappo AS.
    Cancer; 2018 Nov 01; 124(21):4241-4247. PubMed ID: 30204247
    [Abstract] [Full Text] [Related]

  • 3. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF, Demetri GD.
    Future Oncol; 2020 Mar 01; 16(9):417-425. PubMed ID: 32129093
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers.
    Hong DS, Drilon A, Wirth LJ.
    Clin Adv Hematol Oncol; 2024 Mar 01; 22 Suppl 5(6):1-20. PubMed ID: 38953725
    [Abstract] [Full Text] [Related]

  • 5. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
    Caldwell KJ, De La Cuesta E, Morin C, Pappo A, Helmig S.
    Pediatr Blood Cancer; 2020 Sep 01; 67(9):e28330. PubMed ID: 32452122
    [Abstract] [Full Text] [Related]

  • 6. A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report.
    Zhang L, Liu H, Tian Y, Wang H, Yang X.
    BMC Pulm Med; 2021 Apr 17; 21(1):125. PubMed ID: 33865348
    [Abstract] [Full Text] [Related]

  • 7. Testing algorithm for identification of patients with TRK fusion cancer.
    Penault-Llorca F, Rudzinski ER, Sepulveda AR.
    J Clin Pathol; 2019 Jul 17; 72(7):460-467. PubMed ID: 31072837
    [Abstract] [Full Text] [Related]

  • 8. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
    Roth JA, Carlson JJ, Xia F, Williamson T, Sullivan SD.
    J Manag Care Spec Pharm; 2020 Aug 17; 26(8):981-986. PubMed ID: 32329651
    [Abstract] [Full Text] [Related]

  • 9. Improving outcomes in pediatric NTRK gene fusion-positive solid tumors: importance of genomic testing and targeted therapy with the TRK inhibitor larotrectinib.
    Laetsch TW.
    Clin Adv Hematol Oncol; 2024 May 17; 22 Suppl 3(4):1-11. PubMed ID: 38739704
    [No Abstract] [Full Text] [Related]

  • 10. Tropomyosin receptor kinase inhibitors in the management of sarcomas.
    Wilding CP, Loong HH, Huang PH, Jones RL.
    Curr Opin Oncol; 2020 Jul 17; 32(4):307-313. PubMed ID: 32541318
    [Abstract] [Full Text] [Related]

  • 11. Larotrectinib followed by selitrectinib in a novel DCTN1-NTRK1 fusion undifferentiated pleomorphic sarcoma.
    Goh XN, Seng MS, Loh AHP, Gupta A, Chang KTE, Iyer P.
    J Oncol Pharm Pract; 2021 Mar 17; 27(2):485-489. PubMed ID: 32693686
    [Abstract] [Full Text] [Related]

  • 12. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.
    O'Reilly EM, Hechtman JF.
    Ann Oncol; 2019 Nov 01; 30(Suppl_8):viii36-viii40. PubMed ID: 31605106
    [Abstract] [Full Text] [Related]

  • 13. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
    Kummar S, Shen L, Hong DS, McDermott R, Keedy VL, Casanova M, Demetri GD, Dowlati A, Melcón SG, Lassen UN, Leyvraz S, Liu T, Moreno V, Patel J, Patil T, Mallick AB, Sousa N, Tahara M, Ziegler DS, Norenberg R, Arvis P, Brega N, Drilon A, Tan DSW.
    Cancer; 2023 Dec 01; 129(23):3772-3782. PubMed ID: 37769113
    [Abstract] [Full Text] [Related]

  • 14. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
    Yang JCH, Brose MS, Castro G, Kim ES, Lassen UN, Leyvraz S, Pappo A, López-Ríos F, Reeves JA, Fellous M, Penault-Llorca F, Rudzinski ER, Tabatabai G, Vassal G, Drilon A, Trent J.
    BMC Cancer; 2022 Jun 07; 22(1):625. PubMed ID: 35672677
    [Abstract] [Full Text] [Related]

  • 15. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E, Scaltriti M, Drilon A.
    Nat Rev Clin Oncol; 2018 Dec 07; 15(12):731-747. PubMed ID: 30333516
    [Abstract] [Full Text] [Related]

  • 16. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A.
    Ann Oncol; 2019 Nov 07; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [Abstract] [Full Text] [Related]

  • 17. Larotrectinib in NTRK-Rearranged Solid TumorsPublished as part of the Biochemistry series "Biochemistry to Bedside".
    Wilson FH, Herbst RS.
    Biochemistry; 2019 Mar 26; 58(12):1555-1557. PubMed ID: 30865435
    [No Abstract] [Full Text] [Related]

  • 18. [Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
    Delaye M, Rodrigues M.
    Bull Cancer; 2020 Nov 26; 107(11):1085-1086. PubMed ID: 33169692
    [No Abstract] [Full Text] [Related]

  • 19. Loxo TRK inhibitor data wows oncologists.
    Dolgin E.
    Nat Biotechnol; 2017 Aug 08; 35(8):694-695. PubMed ID: 28787403
    [No Abstract] [Full Text] [Related]

  • 20. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
    Kummar S, Berlin J, Mascarenhas L, van Tilburg CM, Geoerger B, Lassen UN, Schilder RJ, Turpin B, Nanda S, Keating K, Childs BH, Chirila C, Laetsch TW, Hyman DM, Drilon A, Hong DS.
    Curr Probl Cancer; 2021 Dec 08; 45(6):100734. PubMed ID: 33865615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.